Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

BACKGROUND: In December 2022, the Taiwan National Health Insurance Administration (NHIA) announced the reimbursement of three dosages of pemigatinib 4.5 mg, 9 mg, and 13.5 mg for treating advanced intrahepatic cholangiocarcinoma (ICC) with fibroblast growth factor receptor 2 (FGFR2) fusions/rearrang...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zi-Rong, Chueh, Chen-Han, Chiang, Nai-Jung, Tsai, Yi-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496386/
https://www.ncbi.nlm.nih.gov/pubmed/37697368
http://dx.doi.org/10.1186/s12962-023-00473-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496386/
https://www.ncbi.nlm.nih.gov/pubmed/37697368
http://dx.doi.org/10.1186/s12962-023-00473-5

Ejemplares similares